Keynote Speaker I - Thursday, March 23rd 2017
Prof. Dr. Jürgen BorlakDirector of the Institute of Pharmaco- and Toxicogenomics,Hannover Medical School, Hannover, Germany
Jürgen Borlak was born in Neu-Ulm, Germany in 1958. After studies at Universities in Germany and abroad he obtained his Doctorate in Pharmacology and Toxicology at the University of Reading, GB. Following postdoctoral residencies in the UK and France (Strasbourg) he was habilitated in pharmacology and toxicology and received the venia legend (“Privatdozent”) at Hannover Medical School in the year 2000. Two years later he was appointed as full professor of Pharmacology and Toxicology at Hannover Medical School. From 2002 onwards he has been the Director of the Institute of Pharmaco- and Toxicogenomics at Hannover Medical School. This new field of genomic science applies a wide range of methods in genetics, molecular biology, molecular toxicology and functional genomics for a better understanding of disease causing mechanisms and drug induced toxicities. An array of enabling technologies are applied for an identification of “drugable” targets and for a better understanding of inter-individual differences in drug response, therefore allowing individualized drug treatment regimens and disease prevention strategies. Jürgen Borlak is also an appointed Professor of Molecular Anatomy at the Medical Faculty of the University Leipzig; a Professor of Experimental Medicine at Uppsala University, Sweden and is Distinguished Visiting Professor at the University of Trento, Italy. Jürgen Borlak is author of > 230 original publications and 25 book chapters and editor of the Handbook of Toxicogenomics. He is reviewer and member of the editorial board for various scientific journals. Amongst others he is an appointed expert of the World Health Organisation (WHO), of the US governmental agency FDA, the European Medicines Agency EMA and the German regulatory agency BfArM. He is also an international reviewer for many European, US and Asian Research Organizations.
Keynote Speaker II - Friday, March 24th 2017
Wendell Jones, Ph.D.Principal Bioinformaticist and Scientific Advisor, Q2 Solutions | EA Genomics, Morrisville, North Carolina
Dr. Jones is currently Principal Bioinformaticist and Scientific Advisor at Q2 Solutions | EA Genomics. He conducts collaborative scientific research with clients in multiple areas, specially in oncology and immuno-oncology. His background includes leading the analysis, development and validation of the bioinformatic and computational systems that process complex genomic assays, including next generation sequencing assays, evaluating new and emerging genomic technologies, and developing bioinformatic implementation strategies. He consults with clients and provides thought leadership in industry and public consortiums involved in genomic science and measurement.
Dr. Jones has over 15 years of experience in advanced genomic technologies and 20 years of experience in scientific and technology leadership positions, including serving as Vice President of Statistics and Bioinformatics at Expression Analysis, Inc (EA) and Chief Science Officer at Reliametrics, a Nortel Networks business unit. He has authored over 30 peer-reviewed publications and has presented at numerous scientific meetings and industry conferences and consortium workshops.
Keynote Speaker III - Saturday, March 25th 2017
John Lazo, Ph.D.
Dr. Lazo is currently the Professor in Pharmacology at the University of Virginia. He received his BA degree in Chemistry from Johns Hopkins University and his doctoral training in Pharmacology from University of Michigan. Dr. Lazo is currently the Harrison Distinguished Teaching Professor in the Department of Pharmacology and holds a secondary appointment in the Department of Chemistry. Professor Lazo served as associate dean for basic research in the School of Medicine at UVA for three and half years. Prior to moving to UVA in 2011, he held the Allegheny Foundation Professorship at the University of Pittsburgh from 1987 until 2010 and was chairman of the Department of Pharmacology from 1987 to 2004. From 2004 until 2010 he was the founding director of the University of Pittsburgh Drug Discovery Institute. His Research Interests include the mechanism of action of small molecules and the fundamental biological role of protein tyrosine phosphatases. For more than 25 years, Dr. Lazo has been involved in studying the cytotoxicity and mechanism of action using cultures human tumor cell lines. He has also been involved in numerous PK-PD studies with anti-cancer agents. He has co-authored 11 books, published more than 340 scientific articles and reviews, holds nine US issued patents, and has trained 13 PhD students and 31 postdoctoral fellows. He founded three companies, one of which (ONTY) is currently listed on NASDAQ.